http://www.zibb.com/healthcare/theme/cq/Dyax+Corporation Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 24 Nov 2009 00:59:21 GMTTue, 24 Nov 2009 00:59:21 GMT608831http://www.zibb.com/healthcare/theme/cq/Dyax+Corporation http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.dyax.com/sitemap.htmlClinical Trials Introduction Learn More About Dyax's Clinical Trials Hereditary Angioedema On-Pump Heart Surgery (DX-88) Cystic Fibrosis (DX-890) New Clinical Press Releases Patient Resources How Trials Work How Do I Enroll? Helpful Links Glossaryhttp://www.dyax.com/sitemap.htmlDyax Corporationhttp://www.epixpharma.com/about/board-of-directors.aspMr. Frank previously served as a Director of Lehman Brothers. Before joining Lehman Brothers as a Partner in October 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Inc.http://www.epixpharma.com/about/board-of-directors.aspDyax Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=56724The current Phase 2 trial for CTS is a 160-patient, randomized, placebo-controlled trial that will be conducted at ten major U.S. cardiac surgery centers.http://www.pharmacychoice.com/News/article.cfm?Article_ID=56724Dyax Corporationhttp://www.fiercebiotech.com/story/dyax-pockets-30m-in-revenue-deal/2006-08-25FierceBiotech is the biotech industry daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and fda approval news.http://www.fiercebiotech.com/story/dyax-pockets-30m-in-revenue-deal/2006-08-25Dyax Corporationhttp://www.pharming.com/index.php?act=news&pg=45There have been a few questions on the press release recently issued by Dyax regarding the temporary halt of their clinical studies of DX-88. Obviously, there is nothing that we can add to what has been described in the public statements.http://www.pharming.com/index.php?act=news&pg=45Dyax Corporationhttp://www.hgsi.com/news/press/00-03-21_dyax.htmlRockville, Maryland, March 21, 2000 -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that it has entered a ten year agreement with Dyax Corp., a privately held company in Cambridge, Massachusetts.http://www.hgsi.com/news/press/00-03-21_dyax.htmlDyax Corporationhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=74772&category=4Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=74772&category=4Dyax Corporationhttp://www.debio.com/e/newsevents/items_e.php?id=89&type=1Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic Fibrosis CAMBRIDGE, MA and LAUSANNE, Switzerland, February 24, 2004 - Dyax Corp. (Nasdaq: DYAX) and Debiopharm S.A.http://www.debio.com/e/newsevents/items_e.php?id=89&type=1Dyax Corporationhttp://www.dyax.com/privacy.aspxAt Dyax Corp., we are committed to respecting your privacy. We understand that facts about a person's demographic, health, health interests, and health care are private and sensitive, and we know that you may have concerns about sharing information with us.http://www.dyax.com/privacy.aspxDyax Corporationhttp://www.dyax.com/disclaimers.htmlAdvancing Novel Therapeutics Dyax Logo Dyax Photo Banner Disclaimers Terms of Use Privacy Policy © Dyax Corp 2004. All rights reserved. Disclaimers Sitemap Homehttp://www.dyax.com/disclaimers.htmlDyax Corporationhttp://www.dyax.com/terms.htmlDyax Corp. is pleased to provide you with this web site and its content for informational purposes. Please carefully read these Terms and Conditions relating to the use of our web site. By using our web site, you agree to these Terms and Conditions.http://www.dyax.com/terms.htmlDyax Corporationhttp://www.dyax.com/discovery/phagedisplay.htmlThe phage display process generally consists of the following steps: (1) generating one or more phage libraries, (2) selecting binding compounds with high affinity and high specificity to a target from the phage display libraries, and (3) producing and evaluating the selected binding compounds.http://www.dyax.com/discovery/phagedisplay.htmlDyax Corporationhttp://www.dyax.com/about/directionsliege.htmlFrom Maastricht: Take Highway E25 from Maastricht to Liege. Follow "E40-E25 Direction Luxemburg" for 25 km; this crosses several tunnels. Continue on E25 toward "Luxemburg". Take Exit "Embourg - Universitity of Liege "C.H.U.". At the exit, bear Right. At the first traffic light, take a Left.http://www.dyax.com/about/directionsliege.htmlDyax Corporationhttp://www.dyax.com/discovery/automation.htmlDyax’s discovery platform extends from its core technological resource: highly diverse phage display libraries. These antibody, small protein and peptide libraries are engineered to provide in excess of one billion unique library members each!http://www.dyax.com/discovery/automation.htmlDyax Corporationhttp://www.dyax.com/clinical/helpfullinks.aspAdvancing Novel Therapeutics Dyax Logo Dyax Photo Banner Product Pipeline Related Information Spotlight: The Science of HAE For scientific information about hereditary angioedema, visit the Online Mendelian Inheritance in Man HAE page. Helpful Links Hereditary Angioedema HAEA - United Stateshttp://www.dyax.com/clinical/helpfullinks.aspDyax Corporationhttp://www.dyax.com/clinical/index.htmlDyax has several products in various stages of clinical development. Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation.http://www.dyax.com/clinical/index.htmlDyax Corporationhttp://www.dyax.com/clinical/howtoenroll.htmlAdvancing Novel Therapeutics Dyax Logo Dyax Photo Banner Clinical Trials Related Information Double-blind? Placebo-controlled? Visit our Glossary to learn the definitions of some common terms used to describe clinical trials, or click the blue glossary links found throughout the clinical trialshttp://www.dyax.com/clinical/howtoenroll.htmlDyax Corporationhttp://www.dyax.com/clinical/pipeline.htmlClinical trials represent a very important stage in the drug development process. These trials are conducted to evaluate the safety of an investigational drug and its efficacy in treating the targeted condition.http://www.dyax.com/clinical/pipeline.htmlDyax Corporationhttp://www.dyax.com/about/benefits.htmlDyax is pleased to offer a competitive benefits package to its eligible full-time U.S. division employees. Employees are generally considered full time for benefits purposes if they are normally scheduled to work an average workweek of at least 40 hours on an annual basis.http://www.dyax.com/about/benefits.htmlDyax Corporationhttp://www.dyax.com/partnerships/inlicensing.html"We are impressed with the speed at which Dyax obtained high affinity and selective protease inhibitors from its antibody libraries to Dendreon's two serine protease targets.http://www.dyax.com/partnerships/inlicensing.htmlDyax Corporationhttp://www.dyax.com/clinical/cardiacsurg.htmlIn on-pump CTS procedures, the heart is stopped, and blood is rerouted through a separate cardiopulmonary bypass (CPB) machine. The heart is filled with a solution to keep it still.http://www.dyax.com/clinical/cardiacsurg.htmlDyax Corporationhttp://www.dyax.com/clinical/clinpipeline.htmlHow does Dyax identify clinical drug candidates? Dyax's patented phage display technology is a powerful engine for the discovery of clinical candidates for Dyax and its collaborators.http://www.dyax.com/clinical/clinpipeline.htmlDyax Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=42685During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays, as well as certain in vivo and preclinical development work.http://www.pharmacychoice.com/News/article.cfm?Article_ID=42685Dyax Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=54694Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Activity on the NASDAQ market has brought this company to the attention of our research team. Dyax Corp.http://www.pharmacychoice.com/News/article.cfm?Article_ID=54694Dyax Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=49059Date: Wednesday, February 21, 2007 Time: 10:00 a.m. ET Telephone Access: Domestic callers, dial 800-659-2056 International callers, dial 617-614-2714 Passcode 50851737 Online Access: Go to the Investor Relations section of the Dyax website (www.dyax.http://www.pharmacychoice.com/News/article.cfm?Article_ID=49059Dyax Corporation